Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer
Economic impact of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer on families
8 evidence topics · 8 sources
Caregiver work changes and quality of life in 345 informal caregivers in the United States, United Kingdom, and Germany
“We conducted a one-time, cross-sectional survey of 345 informal caregivers of people living with mBC in the United States, United Kingdom, and Germany in December 2021.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One in three caregivers changed work status after onset of caregiving, either reducing working hours (12 %), stopping work altogether (13 %), or increasing working hours (8 %). Caregivers who reduced hours or stopped working reported better QoL overall with total CQOLC scores of 71.8 and 65.3, compared to those who maintained or increased work hours (CQOLC scores of 61.3 and 54.4, respectively, [p < 0.001]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Indirect costs of productivity loss for patients and family members, US employer claims
“The MarketScan Health and Productivity Management database (2005-2009) was used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MBC patients had more sick leave cost than controls ($2383 ± $5539 vs. $1282 ± $2083, p < 0.05). Controlling for covariates, MBC patients incurred 47% more short-term disability costs vs EBC patients (p = 0.009).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MBC patients' families incurred 39.7% (p = 0.06) higher indirect costs compared to EBC patients' families after controlling for key covariates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of cancer treatment and work productivity of patients and caregivers
“Of 978 potential citations, 62 articles or abstracts were included. Forty-six studies (74.2%) evaluated patient-related productivity; 10 studies (16.1%) focused on caregivers, and 6 studies (9.7%) were a combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most commonly studied cancer was breast cancer (53.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Metastatic patients’ family members had higher leave days and associated costs than matched patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Workdays missed and indirect costs among employees with newly diagnosed metastatic versus non-metastatic cancer, US claims
“The mean total number of days missing from work for patients with versus without metastases was 33.39 versus 14.91 (ratio = 2.40), 64.05 versus 27.15 (ratio = 2.36), and 105.93 versus 46.29 (ratio = 2.29) days within 3, 6, and 12 months after diagnosis, respectively. Estimates of indirect cost differences between the two groups ranged from $6,877 to $22,283 in the first year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Financial hardship by insurance status in 1054 women with metastatic breast cancer, US national survey
“Participants responded from 41 states (N = 1054; median age: 44 years). Overall, 30% were uninsured.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adjusted analyses, uninsured participants were more likely than insured participants to report contact by debt collectors (adjusted risk ratio [aRR]: 2.38 [2.06, 2.76]) and being unable to meet monthly expenses (aRR: 2.11 [1.68, 2.66]). Financial distress was reported more frequently by insured participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Young adult women with metastatic cancer reported a high burden of financial toxicity. Importantly, insurance does not protect against financial distress; however, the uninsured are the most materially vulnerable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drivers of financial burden and cost-coping behaviors: qualitative interviews with patients and caregiver representatives
“A total of N=11 MBC patients or caregiver representatives participated in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both medical and non-medical costs drove financial burden among participants. All participants reported challenges navigating their health insurance and applying for financial assistance. Regardless of gaining access to assistance, financial burden persisted for nearly all patients and resulted in cost-coping behaviors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even when MBC patients accessed assistance, excess financial burden persisted necessitating use of financial coping-behaviors such as altering medication use, maintaining employment, and taking on debt.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Financial toxicity in 145 women with metastatic breast cancer at a US outpatient clinic
“145 women with metastatic breast cancer receiving care at an urban outpatient breast cancer clinic.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Financial toxicity is common among women with metastatic breast cancer and more common among low-income women with the disease. In addition, financial toxicity is correlated with worse quality of life and overall cancer-related distress.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled rate of financial toxicity in breast cancer: meta-analysis of 66 studies
“Sixty-six studies involving 29 426 participants with breast cancer were enrolled in our study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled FT rate was 39.3% (95% CI, 32.4%-46.6%) in HICs and 72.3% (95% CI, 56.8%-83.8%) in LMICs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote